Arrowhead Pharmaceuticals, Inc. ( NASDAQ: ARWR) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported a larger-than-expected loss for Q1 FY2025, with earnings per share (EPS) at -$1.39, missing the forecast of -$0.39. Revenue also fell short, totaling ...

dense HDL in metabolic disease can be mechanistically related to elevated cholesteryl ester transfer protein activity and to attenuated antiatherogenic function of apolipoprotein AI Deficiency of ...

Identifying the factors involved in NK cell recruitment early in obesity is needed as inhibiting NK cell accumulation within the VAT may serve as a therapeutic avenue to prevent elevated IFNγ levels ...

In a world where the quest for effective weight loss solutions has become increasingly urgent, consumers are presented with many options that often confuse them. BrickHouse Nutrition Lean emerges as a ...